Research programme: proteoglycan-like compounds (vascular injuries) - Symic Biomedical

Drug Profile

Research programme: proteoglycan-like compounds (vascular injuries) - Symic Biomedical

Latest Information Update: 05 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SYMIC Biomedical
  • Class Proteoglycans
  • Mechanism of Action Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Arteriovenous fistula; Vascular disorders

Most Recent Events

  • 26 Aug 2015 Preclinical trials in Arteriovenous fistula in USA (Parenteral)
  • 05 Jan 2015 Preclinical trials in Vascular disorders (Vascular injuries due to surgical or interventional procedures) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top